Search research articles
Contact Us
Filters
Showing results (91-100 of 106) with videos related to
Page
of 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 8, 2024
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
Ryan B Corcoran, Khanh T Do, Jeong E Kim, et al.
Nature Communications
|
October 27, 2017
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman, Yunxin J Jiao, Jonathan H Chen, et al.
JAMA Oncology
|
May 31, 2019
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial
Janet E Murphy, Jennifer Y Wo, David P Ryan, et al.
Cancer Discovery
|
May 22, 2019
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma
Lipika Goyal, Lei Shi, Leah Y Liu, et al.
Nature Reviews. Clinical Oncology
|
July 8, 2020
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper
Arvind Dasari, Van K Morris, Carmen J Allegra, et al.
Cancer Discovery
|
April 30, 2021
<i>FGFR2</i> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma
James M Cleary, Srivatsan Raghavan, Qibiao Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2021
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer
Aparna R Parikh, Emily E Van Seventer, Giulia Siravegna, et al.
Nature Medicine
|
January 26, 2023
Combined PD-1, BRAF and MEK inhibition in BRAF<sup>V600E</sup> colorectal cancer: a phase 2 trial
Jun Tian, Jonathan H Chen, Sherry X Chao, et al.
Nature Medicine
|
November 21, 2019
Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
Aparna R Parikh, Ignaty Leshchiner, Liudmila Elagina, et al.
Nature Medicine
|
September 11, 2019
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
Aparna R Parikh, Ignaty Leshchiner, Liudmila Elagina, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 106) with videos related to
Sort By:
Page
of 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 8, 2024
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
Ryan B Corcoran, Khanh T Do, Jeong E Kim, et al.
Nature Communications
|
October 27, 2017
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman, Yunxin J Jiao, Jonathan H Chen, et al.
JAMA Oncology
|
May 31, 2019
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial
Janet E Murphy, Jennifer Y Wo, David P Ryan, et al.
Cancer Discovery
|
May 22, 2019
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma
Lipika Goyal, Lei Shi, Leah Y Liu, et al.
Nature Reviews. Clinical Oncology
|
July 8, 2020
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper
Arvind Dasari, Van K Morris, Carmen J Allegra, et al.
Cancer Discovery
|
April 30, 2021
<i>FGFR2</i> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma
James M Cleary, Srivatsan Raghavan, Qibiao Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2021
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer
Aparna R Parikh, Emily E Van Seventer, Giulia Siravegna, et al.
Nature Medicine
|
January 26, 2023
Combined PD-1, BRAF and MEK inhibition in BRAF<sup>V600E</sup> colorectal cancer: a phase 2 trial
Jun Tian, Jonathan H Chen, Sherry X Chao, et al.
Nature Medicine
|
November 21, 2019
Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
Aparna R Parikh, Ignaty Leshchiner, Liudmila Elagina, et al.
Nature Medicine
|
September 11, 2019
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
Aparna R Parikh, Ignaty Leshchiner, Liudmila Elagina, et al.
Page
of 11